// App-Quantinova.ai

TPS3153 : A first-in-human phase I study of ATR inhibitor M1774 in patients with solid tumors.

Researchers

Presenter

  • Timothy A. Yap

Principal Investigators

  • Anthony W. Tolcher

  • Elizabeth Ruth Plummer

  • Andreas Becker

  • Patricia Fleuranceau-Morel

  • Thomas Goddemeier

  • Giuseppe Locatelli

  • Ioannis Gounaris

  • Johann S. De Bono

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Texas Oncology, San Antonio, TX

  • Newcastle University and Northern Centre for Cancer Care, Newcastle Hospitals NHS Trust, Newcastle upon Tyne, United Kingdom

  • Merck KGaA, Darmstadt, Germany

  • EMD Serono Research and Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA

  • Merck Serono Ltd. (an affiliate of Merck KGaA, Darmstadt, Germany), Feltham, United Kingdom

  • Royal Marsden Hospital, Surrey, United Kingdom

Locations

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • Solid malignancies

  • ATRX syndrome

Biomarkers

  • Alpha thalassemia mental retardation X-linked protein

  • Ataxia Telangiectasia And Rad3-Related Protein

  • AT-rich interactive domain 1A

  • Alanine transaminase

  • Death Domain Associated Protein

  • Ataxia-telangiectasia mutated

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Cross Over

  • Dose Escalation

  • First-In-Human

Phase

  • I

Study Id's

  • NCT04170153

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved